Polyphron
New City, New York, United States
About Polyphron
Polyphron builds an autonomous tissue foundry platform for scalable, reproducible human tissue manufacturing. The company uses induced pluripotent stem cells, AI models, and automation to engineer graftable human tissues across cortical, cardiac, and other tissue contexts. Its platform integrates developmental single-cell atlases, high-throughput 3D tissue experiments, and active learning to optimize tissue structure and polarity. Polyphron develops biomanufacturing systems for difficult-to-produce proteins, high-fidelity safety and efficacy screening tissues, and immune-compatible iPSC-derived grafts intended to restore tissue function and support regenerative medicine applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Seed
- Last round: Seed (Jan 2026)
- Website: polyphron.com
Social Profiles
Canonical: https://fsome.com/organization/polyphron-2488018 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.